Lineage Cell Therapeutics
LCTX
74 hedge funds and large institutions have $98.6M invested in Lineage Cell Therapeutics in 2015 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 13 closing their positions.
3.4% more ownership
Funds ownership: 46.25% → 49.66% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 80 → 74 (-6)
13% less capital invested
Capital invested by funds: $113M → $98.6M (-$14.2M)
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
78% less call options, than puts
Call options by funds: $113K | Put options by funds: $508K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$7.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$646K |
| 3 |
Jane Street
New York
|
+$402K |
| 4 |
V
Veritable
Wilmington,
Delaware
|
+$241K |
| 5 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$144K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$774K |
| 2 |
Renaissance Technologies
New York
|
-$599K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$411K |
| 4 |
CCM
Consonance Capital Management
New York
|
-$372K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$253K |
LCTX Hedge Fund Activity: Q3 2015 in Review
74 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2015, worth a combined $98.6M — down 13% from $113M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of LCTX and 7 opened new positions — a net loss of 6 holders — while 24 trimmed existing stakes and 18 added.
The largest buyer was Broadwood Capital, adding an estimated $7.8M. The largest seller was TFS Capital, cutting an estimated $774K.
- 74 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2015, down from 80 in Q2 2015.
- Funds reported $98.6M of Lineage Cell Therapeutics stock for Q3 2015, down 13% quarter-over-quarter.
- 7 funds opened new Lineage Cell Therapeutics positions in Q3 2015 and 13 closed out, a net change of -6 holders.
- The largest Lineage Cell Therapeutics buyer in Q3 2015 was Broadwood Capital, an estimated $7.8M added.
- The largest Lineage Cell Therapeutics seller in Q3 2015 was TFS Capital, an estimated $774K sold.
Based on aggregated 13F filings for Q3 2015.